Japan’s Shionogi says COVID-19 treatment failed to meet endpoint in late-stage trial
TOKYO – Japan’s Shionogi & Co said on Monday its drug-based treatment for COVID-19 did not meet its primary endpoint of showing a statistically significant reduction in 15 common symptoms of the disease in a global late-stage trial. Japan’s Shionogi says COVID-19 treatment failed to meet endpoint in late-stage trial The company said its pivotal … Read more